Clinical trial · no report yet · Phase 1
NCT06343402
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- NCT06343402 ↗
- Recruiting
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma
- Interventions
- BBO-8520; Pembrolizumab; BBO-10203
- Arms
- Cohort 1a - Dose Escalation/Dose Finding Monotherapy · Experimental
- Cohort 1b - Dose Escalation/Dose Finding Combination Therapy · Experimental
- Cohort 2a - Dose Expansion Monotherapy · Experimental
- Cohort 2b - Dose Expansion Combination Therapy · Experimental
- Cohort 1b Safety Lead-In - Dose Expansion Doublet Combination Therapy · Experimental
- Cohort 1b - Dose Expansion Doublet Combination Therapy · Experimental
- Cohort 1b Safety Lead-In - Dose Expansion Triplet Combination Therapy · Experimental
- Cohort 1b - Dose Expansion Triplet Combination Therapy · Experimental
- Enrollment
- 350 (estimated)
- Primary outcomes
- Adverse Events
- Dose-limiting toxicities (DLTs)
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Start
- May 22, 2024
- Primary completion
- Apr 2031 (estimated)
- Results posted
- No
- Registry record
- NCT06343402 · updated Sep 3, 2026